Fennec Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Fennec Pharmaceuticals generated cash of -$17,143,000, which is more than the previous year. Cash used in financing activities reached the amount of $6,638,000 last year. Net change in cash is therefore -$10,505,000.
Cash Flow
| 2014 | -1.69M | 0 | 2.34M |
|---|---|---|---|
| 2015 | -1.86M | 0 | 497K |
| 2016 | -2.12M | 0 | 5.10M |
| 2017 | -3.64M | 0 | 27.97M |
| 2018 | -7.82M | 0 | 2.34M |
| 2019 | -9.06M | 0 | -71K |
| 2020 | -15.59M | 0 | 32.28M |
| 2021 | -14.22M | 0 | 4.97M |
| 2022 | -18.05M | 0 | 20.73M |
| 2023 | -17.14M | 0 | 6.63M |
FENC Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 23.77M | 21.1M | 30.34M | 13.65M | 22.78M | 28.26M | 3.92M | 942K | 2.30M | 1.66M |
Operating activities | ||||||||||
Net income | -16.04M | -23.71M | -17.34M | -18.10M | -12.77M | -9.88M | -7.04M | -2.78M | -659K | -2.17M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 132K | 14K | 402K | 64K | 0 | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 5.35M | 4.22M | 3.74M | 2.79M | 3.08M | 0 | 1.51M | 615K | 97K | 627K |
| Deferred income tax benefit | 5.35M | 4.22M | 3.74M | 2.79M | 3.08M | 0 | 1.51M | 615K | 97K | 627K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -7.40M | -1.54M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | -1.60M | -576K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 1.41M | 1.61M | -794K | -41K | 580K | 177K | 611K | -54K | -11K | 0 |
Cash generated by operating activities | -17.14M | -18.05M | -14.22M | -15.59M | -9.06M | -7.82M | -3.64M | -2.12M | -1.86M | -1.69M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Financing activities | ||||||||||
Common Stock Issued | 1.74M | 723.16K | -7.92K | 33.99M | 0 | 2.21M | 27.38M | 0 | 457.74K | 2.18M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -78K | -194K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 4.99M | 19.93M | -4.94M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 6.63M | 20.73M | 4.97M | 32.28M | -71K | 2.34M | 27.97M | 5.10M | 497K | 2.34M |
Net Change In Cash | -10.50M | 2.67M | -9.24M | 16.69M | -9.13M | -5.47M | 24.33M | 2.98M | -1.36M | 644K |
Cash at end of period | 13.26M | 23.77M | 21.1M | 30.34M | 13.65M | 22.78M | 28.26M | 3.92M | 942K | 2.30M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |